Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 16/20 | 0.59 |
| ▸ | AXL | P30530 | 2/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 13/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.54 |
| ▸ | MET | P08581 | 5/20 | 0.54 |
| ▸ | FLT3 | P36888 | 4/20 | 0.54 |
| ▸ | KDR | P35968 | 4/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12852944 | 0.99 | CSF1R (0.59) | CSF1RAXLPDGFRAPDGFRBMET | |
| SCHEMBL2411319 | 0.92 | CSF1R (0.59) | CSF1RAXLPDGFRAPDGFRBMET | |
| SCHEMBL2450218 | 0.91 | CSF1R (0.57) | CSF1RAXLPDGFRAPDGFRBMET | |
| SCHEMBL29883490 | 0.91 | CSF1R (0.57) | CSF1RAXLPDGFRAPDGFRBMET | |
| Lithium Ion SCHEMBL2414962 | 0.91 | CSF1R (0.58) | CSF1RAXLPDGFRAPDGFRBMET | |
| Hydrochloric Acid SCHEMBL2452300 | 0.90 | CSF1R (0.58) | CSF1RAXLPDGFRAPDGFRBMET | |
| SCHEMBL2411263 | 0.89 | MET (0.64) | CSF1RAXLPDGFRAPDGFRBMET | |
| SCHEMBL2413206 | 0.89 | AXL (0.56) | CSF1RAXLPDGFRAPDGFRBMET | |
| SCHEMBL2412919 | 0.88 | CSF1R (0.67) | CSF1RAXLPDGFRAPDGFRBMET | |
| SCHEMBL2414859 | 0.87 | AXL (0.57) | CSF1RAXLPDGFRAPDGFRBMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2365752-B1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8486951-B2 | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130079362-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-03-28 | — | — | US | disclosed |
| US-8278331-B2 | N-acyl ureas exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100120806-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079362-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | KIT, PDGFRA, PDGFRB | CSF1R 14/4885AXL 439/4885PDGFRA 2/4885 |
| US-20100120806-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | KIT, PDGFRA, PDGFRB | CSF1R 9/4885AXL 441/4885PDGFRA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.